NCT04081103Phase 2Terminated

NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2022-02-07Actual

Enrollment · participants35Actual

Source updated2025-07-14Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Corneal Persistent Epithelial Defect

Treatments or interventions studied

Nexagon® (lufepirsen) High Dose ConcentrationDrug
Nexagon® (lufepirsen) Low Dose ConcentrationDrug
VehicleDrugAlso known as Placebo
Open-label Nexagon® (lufepirsen)Drug

Primary outcomes · main study measures

Read the study measures

measure: The Proportion of Subjects Achieving Corneal Epithelial Recovery, as Assessed by Slit Lamp Examination.; description: Corneal epithelial recovery, defined as corneal reepithelialization and maintenance of a durable epithelium for at least 28 days, will be assessed by slit lamp examination.; timeFrame: Up to 56 days.; measure: Incidence of Treatment Emergent Adverse Events as Assessed by CTCAE v 5.0; description: Incidence of Treatment Emergent Adverse Events as assessed by CTCAE v 5.0.; timeFrame: Up to 30 days after last application of intervention

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history